Fresenius Medical to take $600M stake in Sound Inpatient Physicians Fresenius Medical Care has entered into an agreement to invest approximately $600M in Sound Inpatient Physicians to become majority shareholder as part of a recapitalization of Sound, alongside existing investor TowerBrook Capital Partners and Soundís senior leadership team. The transaction is subject to customary closing conditions and is expected to close within the next ten days.
Flamel Technologies price target lowered to $17 from $22 at Roth Capital Roth Capital cut its price target on Flamel (FLML) after the FDA approved Fresenius Kabi's (FMS) New Drug Application for neostigmine methylsulfate, a drug which Flamel currently markets as Bloxiverz. Roth expects eostigmine to become a two player market, but adds that price increases by Flamel could mitigate the negative impacts on Flamel's growth. The firm keeps a Buy rating on Flamel.
JPMorgan to hold a conference 33rd Annual Healthcare Conference is being held in San Francisco on January 12-15 with webcasted company presentations to begin on January 13 at 10:30 am; not all company presentations may be webcasted. Webcast Link